Skip to main content

Clinical trial ORIENT-15

A Multicenter, Double-blind, Randomised Phase 3 Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination with Chemotherapy, for First-line Treatment of Unresectable, Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Cancers
Organ Esophagus
Trial status Trial open for recruitment
Investigator
Trial type
Interventional with experimental drug
Phase Trial phase 3
Academic trial Non
Sponsor Innovent Biologics (Suzhou) Co., Ltd.
EudraCT Identifier 2020-000533-40
ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03748134
Last update